Syneron Medical Company Profile (NASDAQ:ELOS)

About Syneron Medical (NASDAQ:ELOS)

Syneron Medical logoSyneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company's products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ELOS
  • CUSIP: N/A
  • Web:
  • Market Cap: $380.39 million
  • Outstanding Shares: 34,898,000
Average Prices:
  • 50 Day Moving Avg: $10.97
  • 200 Day Moving Avg: $9.60
  • 52 Week Range: $6.18 - $11.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 19.82
  • P/E Growth: 0.82
Sales & Book Value:
  • Annual Revenue: $296.29 million
  • Price / Sales: 1.28
  • Book Value: $5.90 per share
  • Price / Book: 1.85
  • EBIDTA: $13.4 million
  • Net Margins: 1.04%
  • Return on Equity: 3.15%
  • Return on Assets: 2.34%
  • Current Ratio: 2.94%
  • Quick Ratio: 2.19%
  • Average Volume: 839,682 shs.
  • Beta: 1.1
  • Short Ratio: 0.75

Frequently Asked Questions for Syneron Medical (NASDAQ:ELOS)

What is Syneron Medical's stock symbol?

Syneron Medical trades on the NASDAQ under the ticker symbol "ELOS."

How were Syneron Medical's earnings last quarter?

Syneron Medical Ltd. (NASDAQ:ELOS) posted its earnings results on Thursday, August, 4th. The company reported $0.09 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.03. The company had revenue of $75 million for the quarter, compared to analyst estimates of $75.72 million. Syneron Medical had a return on equity of 3.15% and a net margin of 1.04%. The company's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the company earned $0.07 earnings per share. View Syneron Medical's Earnings History.

Where is Syneron Medical's stock going? Where will Syneron Medical's stock price be in 2017?

3 brokers have issued 1-year target prices for Syneron Medical's stock. Their forecasts range from $7.80 to $13.00. On average, they anticipate Syneron Medical's stock price to reach $10.60 in the next twelve months. View Analyst Ratings for Syneron Medical.

What are analysts saying about Syneron Medical stock?

Here are some recent quotes from research analysts about Syneron Medical stock:

  • 1. Maxim Group analysts commented, "On May 10, 2017, ELOS announced the expiration of the go-shop" period under its merger agreement with Apax Partners. During the go-shop period, ELOS engaged in an active and extensive solicitation of 59 potential bidders, which resulted in two potential bidders each negotiating and entering into a confidentiality agreement. However, they subsequently confirmed that they weren’t interested in pursuing an acquisition of ELOS. The acquisition by Apax Partners is expected to be completed during 3Q17, subject to ELOS shareholder approval and the satisfaction of other customary closing conditions." (5/12/2017)
  • 2. According to Zacks Investment Research, "Syneron Medical Ltd. manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented ELOS combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative ELOS technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications. " (1/11/2017)

Who are some of Syneron Medical's key competitors?

Who owns Syneron Medical stock?

Syneron Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Brandes Investment Partners LP (10.51%), North Tide Capital LLC (8.57%), Camber Capital Management LLC (6.70%), SAND GROVE CAPITAL MANAGEMENT LLP (5.20%), Dalton Greiner Hartman Maher & Co. (4.70%) and SAND GROVE CAPITAL MANAGEMENT LLP (4.30%). View Institutional Ownership Trends for Syneron Medical.

Who sold Syneron Medical stock? Who is selling Syneron Medical stock?

Syneron Medical's stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Menora Mivtachim Holdings LTD., Dalton Greiner Hartman Maher & Co., TFS Capital LLC, Ameriprise Financial Inc., Renaissance Technologies LLC, Geode Capital Management LLC and Creative Planning. View Insider Buying and Selling for Syneron Medical.

Who bought Syneron Medical stock? Who is buying Syneron Medical stock?

Syneron Medical's stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Systematic Financial Management LP, Profit Investment Management LLC, Driehaus Capital Management LLC, Clough Capital Partners L P, Menta Capital LLC, Bogle Investment Management L P DE and Jane Street Group LLC. View Insider Buying and Selling for Syneron Medical.

How do I buy Syneron Medical stock?

Shares of Syneron Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Syneron Medical stock cost?

One share of Syneron Medical stock can currently be purchased for approximately $10.90.

Analyst Ratings

Consensus Ratings for Syneron Medical (NASDAQ:ELOS) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $10.60 (2.75% downside)

Analysts' Ratings History for Syneron Medical (NASDAQ:ELOS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Maxim GroupDowngradeBuy -> Hold$12.00 -> $11.00MediumView Rating Details
10/24/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
8/5/2016Leerink SwannDowngradeOutperform -> Market Perform$9.40 -> $7.80N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Syneron Medical (NASDAQ:ELOS)
Earnings by Quarter for Syneron Medical (NASDAQ:ELOS)
Earnings History by Quarter for Syneron Medical (NASDAQ:ELOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2017Q416$0.03($0.03)$82.02 million$82.90 millionViewListenView Earnings Details
11/9/2016Q316($0.02)$0.02$68.08 million$71.50 millionViewListenView Earnings Details
8/4/2016Q216$0.06$0.09$75.72 million$75.00 millionViewListenView Earnings Details
5/19/2016Q116$0.01$0.04$64.38 million$68.70 millionViewListenView Earnings Details
2/22/2016Q415$0.07$0.07$75.56 million$78.90 millionViewListenView Earnings Details
11/11/2015Q315$0.03$0.03$66.60 million$62.10 millionViewListenView Earnings Details
8/4/2015Q215$0.06$0.04$70.93 million$73.50 millionViewN/AView Earnings Details
5/13/2015Q115$0.01$0.02$62.08 million$63.40 millionViewListenView Earnings Details
2/18/2015Q414$0.06$0.09$71.42 million$74.10 millionViewN/AView Earnings Details
11/12/2014Q314$0.03$0.03$58.32 million$60.30 millionViewN/AView Earnings Details
8/6/2014Q214$0.07$0.07$63.52 million$64.60 millionViewListenView Earnings Details
5/14/2014Q114$0.04$0.04$55.50 million$56.80 millionViewN/AView Earnings Details
2/20/2014Q413$0.08$0.11$65.70 million$64.30 millionViewListenView Earnings Details
11/13/2013Q313$0.01$0.04$62.06 million$62.70 millionViewListenView Earnings Details
8/14/2013Q2 2013$0.09$0.02$70.93 million$68.80 millionViewN/AView Earnings Details
5/22/2013Q1 2013$0.02$0.02$61.19 million$61.20 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.11$70.60 million$72.80 millionViewN/AView Earnings Details
11/7/2012Q312$0.04$0.03$65.51 million$60.13 millionViewN/AView Earnings Details
8/15/2012$0.04$0.05ViewN/AView Earnings Details
2/9/2012$0.04$0.03ViewN/AView Earnings Details
11/10/2011($0.09)($0.03)ViewN/AView Earnings Details
8/11/2011($0.02)($0.01)ViewN/AView Earnings Details
5/19/2011($0.04)$0.01ViewN/AView Earnings Details
2/16/2011($0.04)$0.24ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Syneron Medical (NASDAQ:ELOS)
Current Year EPS Consensus Estimate: $0.38 EPS
Next Year EPS Consensus Estimate: $0.55 EPS


Dividend History for Syneron Medical (NASDAQ:ELOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Syneron Medical (NASDAQ:ELOS)
No insider trades for this company have been tracked by


Headline Trends for Syneron Medical (NASDAQ:ELOS)
Latest Headlines for Syneron Medical (NASDAQ:ELOS)
DateHeadline logoSyneron Medical Ltd. – Value Analysis (NASDAQ:ELOS) : May 18, 2017 - May 18 at 5:28 PM logoSyneron Medical Reports First Quarter 2017 Revenue of $66.9 Million - May 17 at 9:59 PM logoSyneron Medical reports 1Q loss - May 17 at 9:59 PM logoSyneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : May 17, 2017 - May 17 at 10:59 AM logoSyneron Medical Ltd. (ELOS) Cut to "Hold" at Maxim Group - May 12 at 8:20 AM logoSyneron Candela (ELOS) Announces Expiration of Go-Shop Period - May 10 at 5:06 PM logoSyneron Candela Announces End of Go-Shop Period - May 10 at 7:26 AM logoSyneron Medical (ELOS) Given Media Sentiment Rating of 0.14 - May 3 at 1:26 PM logoSyneron Medical (ELOS) Receives News Sentiment Score of 0.56 - April 29 at 9:43 AM logoSyneron Medical (ELOS) Earns Coverage Optimism Score of 0.14 - April 24 at 3:40 PM logoSyneron Medical (ELOS) Receives News Impact Score of 0.10 - April 20 at 5:00 PM logoSyneron Medical (ELOS) Getting Very Positive Press Coverage, Analysis Shows - April 15 at 8:26 AM logoApax to buy Israeli aesthetic device firm Syneron for $397 mln - April 3 at 10:17 PM logoApax to buy Israeli aesthetic device firm Syneron for $397 million - April 3 at 10:17 PM logoSyneron Medical (ELOS) Jumps on Apax Deal - April 3 at 5:16 PM logoSyneron Medical Agrees To Be Bought By Apax Partners For $397 Mln - Quick Facts - April 3 at 5:16 PM logoSyneron Medical Ltd. stock rises after nearly $400 mln acquisition of outstanding shares - April 3 at 5:16 PM logoApax eyes IPO for investment house Psagot in Tel Aviv -source - April 3 at 7:18 AM logoSyneron Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for $11.00/share in Cash, Representing an Approximate Value of $397 Million - April 3 at 7:18 AM logoApax close to $500 mln deal to buy Israel's Syneron - reports - April 2 at 8:31 AM logoSYNERON MEDICAL LTD. Financials - March 29 at 5:28 PM logoForm 6-K Syneron Medical Ltd. For: Mar 27 - - March 28 at 9:40 PM logoSyneron Candela Announces CE Mark for CO2RE® Intima - March 27 at 11:59 AM logoSyneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website - March 23 at 5:28 PM logoSyneron Candela Announces New Technology and Indications at the 2017 American Academy of Dermatology (AAD) Annual Meeting - March 1 at 4:39 PM logoSyneron Medical: Still Frustrating - And Still Tantalizing - Seeking Alpha - February 24 at 5:43 PM logoSyneron Medical 4Q Loss 3 Cents a Share (ELOS) - February 16 at 4:40 PM logoSyneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million - February 16 at 4:40 PM logo7:02 am Syneron Medical beats by $0.05, beats on revs - February 16 at 4:40 PM logoQ4 2016 Syneron Medical Ltd Earnings Release - Before Market Open - February 16 at 4:40 PM logoSyneron Medical Reports 4Q Loss of 3 Cents a Share - February 16 at 4:40 PM logoEdited Transcript of ELOS earnings conference call or presentation 15-Feb-17 1:30pm GMT - February 16 at 7:42 AM logoUPDATE 2-Hologic buys Cynosure to expand into medical aesthetics - Nasdaq - February 14 at 5:51 PM logoSyneron Medical to Participate in Leerink Partners 6th Annual Global Healthcare Conference - February 13 at 5:42 PM logoApax Partners in talks to buy Israel's Syneron Medical -report - February 13 at 7:43 AM logoSientra (SIEN) Names Philippe Schaison to Board of Directors - February 7 at 6:06 PM logoSientra Appoints Aesthetic Industry Leader Philippe A. Schaison to Board of Directors - February 7 at 6:06 PM logoSyneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources - PR Newswire (press release) - January 31 at 5:37 PM logoSyneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources Officer - January 31 at 5:37 PM logoSyneron Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017 - January 30 at 12:24 PM



Syneron Medical (ELOS) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff